IMNM
Immunome, Inc.
Price Chart
Latest Quote
$20.68
+0.93 (+4.71%)
Current Price
| Previous Close | $19.75 |
| Open | $19.57 |
| Day High | $21.09 |
| Day Low | $19.57 |
| Volume | 445,049 |
Stock Information
| Shares Outstanding | 113.25M |
| Total Debt | $3.69M |
| Cash Equivalents | $582.69M |
| Revenue | $4.01M |
| Net Income | $-224.59M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.34B |
| EPS (TTM) | $-2.39 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.66B |
| Sales | $4.01M |
| Income | $-224.59M |
| Book/sh | $5.20 |
| Cash/sh | $5.15 |
| Employees | 206 |
Financial Ratios
| Quick Ratio | 21.26 |
| Current Ratio | 21.68 |
| Debt/Eq | 0.63 |
Returns & Margins
| ROA | -29.72% |
| ROE | -50.14% |
| Operating Margin | -5698.83% |
Ownership
| Insider Ownership | 6.30% |
| Institutional Ownership | 108.39% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.86 |
| P/S | 583.32 |
| P/B | 3.98 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $35.77 |
Technical Indicators
| SMA20 | $19.33 |
| SMA50 | $21.34 |
| SMA200 | $19.53 |
| RSI | 59.92 |
| ATR | 0.8439 |
| Shares Float | 108.33M |
| Short Float | 17.42% |
| Short Ratio | 16.40 |
| Volatility | 2.07 |
| Rel Volume | 0.31 |
Performance History
| Week | +11.60% |
| Month | -5.61% |
| Quarter | +1.87% |
| 6 Months | -6.13% |
| YTD | -0.67% |
| Year | +131.84% |
| 3 Years | +264.08% |
| 5 Years | +23.10% |
| 10 Years | +53.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $20.68 | 445,049 |
| 2026-06-24 | $19.75 | 1,531,500 |
| 2026-06-23 | $19.33 | 2,175,000 |
| 2026-06-22 | $19.18 | 1,232,600 |
| 2026-06-18 | $18.74 | 3,318,500 |
| 2026-06-17 | $18.53 | 1,419,700 |
| 2026-06-16 | $17.91 | 877,500 |
| 2026-06-15 | $18.07 | 905,100 |
| 2026-06-12 | $18.38 | 2,066,400 |
| 2026-06-11 | $18.36 | 2,002,600 |
| 2026-06-10 | $18.16 | 1,140,800 |
| 2026-06-09 | $18.39 | 1,077,300 |
| 2026-06-08 | $18.61 | 1,094,600 |
| 2026-06-05 | $18.58 | 895,700 |
| 2026-06-04 | $19.68 | 878,400 |
| 2026-06-03 | $19.81 | 1,247,300 |
| 2026-06-02 | $19.34 | 2,835,400 |
| 2026-06-01 | $20.78 | 1,524,400 |
| 2026-05-29 | $21.83 | 1,727,600 |
| 2026-05-28 | $22.54 | 501,300 |
| 2026-05-27 | $22.11 | 879,500 |
| 2026-05-26 | $21.91 | 1,094,600 |
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
đ° Latest News
4 Biotech Stocks Investors Should Watch in 2026
Zacks âĸ 2026-06-05T14:54:00Z
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-06-05T02:13:13Z
Barclays initiates oncology-focused biotechs with positive outlook
Investing.com âĸ 2026-05-28T15:26:11ZWhat Offers Immunome (IMNM) a Compelling Investment Opportunity?
Insider Monkey âĸ 2026-05-18T12:54:41Z
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors
Insider Monkey âĸ 2026-05-12T00:01:35Z
Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success
Simply Wall St. âĸ 2026-05-11T07:13:35Z
Techne (TECH) Misses Q3 Earnings and Revenue Estimates
Zacks âĸ 2026-05-06T11:45:06Z
Exelixis (EXEL) Tops Q1 Earnings Estimates
Zacks âĸ 2026-05-05T21:15:03Z
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-04T23:30:03Z
A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing
Simply Wall St. âĸ 2026-04-25T11:04:09Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $6,941,000 | $9,041,000 | $14,018,000 | $0 |
| Operating Revenue | $6,941,000 | $9,041,000 | $14,018,000 | $0 |
| Expenses | ||||
| Total Expenses | $231,054,000 | $162,497,000 | $42,746,000 | $36,901,000 |
| Net Non Operating Interest Income Expense | $11,719,000 | $12,837,000 | $2,724,000 | $5,000 |
| Operating Expense | $231,054,000 | $162,497,000 | $42,746,000 | $36,901,000 |
| General And Administrative Expense | $43,768,000 | $32,955,000 | $19,657,000 | $13,629,000 |
| Other Income Expense | - | $-152,344,000 | $-80,802,000 | - |
| Total Other Finance Cost | - | - | - | $-5,000 |
| Interest Expense | - | - | - | - |
| Other Non Operating Income Expenses | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-212,394,000 | $-292,963,000 | $-106,806,000 | $-36,896,000 |
| Net Interest Income | $11,719,000 | $12,837,000 | $2,724,000 | $5,000 |
| Interest Income | $11,719,000 | $12,837,000 | $2,724,000 | $5,000 |
| Normalized Income | $-212,394,000 | $-140,619,000 | $-26,004,000 | $-36,896,000 |
| Net Income From Continuing And Discontinued Operation | $-212,394,000 | $-292,963,000 | $-106,806,000 | $-36,896,000 |
| Total Operating Income As Reported | $-224,113,000 | $-305,800,000 | $-109,530,000 | $-36,901,000 |
| Net Income Common Stockholders | $-212,394,000 | $-292,963,000 | $-106,806,000 | $-37,518,000 |
| Net Income | $-212,394,000 | $-292,963,000 | $-106,806,000 | $-36,896,000 |
| Net Income Including Noncontrolling Interests | $-212,394,000 | $-292,963,000 | $-106,806,000 | $-36,896,000 |
| Net Income Continuous Operations | $-212,394,000 | $-292,963,000 | $-106,806,000 | $-36,896,000 |
| Pretax Income | $-212,394,000 | $-292,963,000 | $-106,806,000 | $-36,896,000 |
| Interest Income Non Operating | $11,719,000 | $12,837,000 | $2,724,000 | $5,000 |
| Operating Income | $-224,113,000 | $-153,456,000 | $-28,728,000 | $-36,901,000 |
| Special Income Charges | - | $-152,344,000 | $-80,802,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-2.43 | $-5.00 | $-5.38 | $-3.09 |
| Basic EPS | $-2.43 | $-5.00 | $-5.38 | $-3.09 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-221,158,000 | $990,000 | $52,802,000 | $-36,270,000 |
| Reconciled Depreciation | $2,955,000 | $2,102,000 | $728,000 | $631,000 |
| EBITDA (Bullshit earnings) | $-221,158,000 | $-151,354,000 | $-28,000,000 | $-36,270,000 |
| EBIT | $-224,113,000 | $-153,456,000 | $-28,728,000 | $-36,901,000 |
| Diluted Average Shares | $87,350,956 | $58,639,441 | $19,843,651 | $12,126,573 |
| Basic Average Shares | $87,350,956 | $58,639,441 | $19,843,651 | $12,126,573 |
| Diluted NI Availto Com Stockholders | $-212,394,000 | $-292,963,000 | $-106,806,000 | $-37,518,000 |
| Research And Development | $187,286,000 | $129,542,000 | $23,089,000 | $23,272,000 |
| Selling General And Administration | $43,768,000 | $32,955,000 | $19,657,000 | $13,629,000 |
| Other Gand A | $43,768,000 | $32,955,000 | $19,657,000 | $13,629,000 |
| Total Unusual Items | - | $-152,344,000 | $-80,802,000 | $0 |
| Total Unusual Items Excluding Goodwill | - | $-152,344,000 | $-80,802,000 | $0 |
| Other Special Charges | - | $152,344,000 | $80,802,000 | - |
| Restructuring And Mergern Acquisition | - | $152,344,000 | $80,802,000 | $0 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $622,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $634,343,000 | $181,165,000 | $119,882,000 | $16,653,000 |
| Total Assets | $683,188,000 | $240,241,000 | $148,540,000 | $24,046,000 |
| Total Non Current Assets | $22,411,000 | $18,902,000 | $3,837,000 | $1,397,000 |
| Other Non Current Assets | $4,797,000 | $4,511,000 | $200,000 | $100,000 |
| Current Assets | $660,777,000 | $221,339,000 | $144,703,000 | $22,649,000 |
| Other Current Assets | $7,295,000 | $4,036,000 | $6,561,000 | $876,000 |
| Cash Cash Equivalents And Short Term Investments | $653,482,000 | $217,303,000 | $138,142,000 | $20,323,000 |
| Cash And Cash Equivalents | $653,482,000 | $143,351,000 | $98,679,000 | $20,323,000 |
| Non Current Deferred Assets | - | - | $0 | $332,000 |
| Prepaid Assets | - | - | $2,004,000 | $1,479,000 |
| Receivables | - | - | $289,000 | $847,000 |
| Taxes Receivable | - | - | $0 | $847,000 |
| Accrued Interest Receivable | - | - | $289,000 | $0 |
| Accounts Receivable | - | - | - | $847,000 |
| Other Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $3,855,000 | $4,832,000 | $1,650,000 | $291,000 |
| Long Term Debt And Capital Lease Obligation | $3,855,000 | $4,769,000 | $1,340,000 | $62,000 |
| Current Debt And Capital Lease Obligation | - | $63,000 | $310,000 | $229,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $48,845,000 | $59,076,000 | $28,658,000 | $7,393,000 |
| Total Non Current Liabilities Net Minority Interest | $3,855,000 | $4,769,000 | $6,829,000 | $62,000 |
| Current Liabilities | $44,990,000 | $54,307,000 | $21,829,000 | $7,331,000 |
| Other Current Liabilities | $3,626,000 | $7,978,000 | $732,000 | $86,000 |
| Current Deferred Liabilities | $0 | $6,941,000 | $10,493,000 | $0 |
| Payables And Accrued Expenses | $29,837,000 | $33,464,000 | $6,124,000 | $5,142,000 |
| Payables | $3,339,000 | $14,189,000 | $3,311,000 | $2,400,000 |
| Accounts Payable | $3,339,000 | $14,189,000 | $3,311,000 | $2,400,000 |
| Non Current Deferred Liabilities | - | $0 | $5,489,000 | $0 |
| Other Non Current Liabilities | - | - | - | $62,000 |
| Equity | ||||
| Common Stock Equity | $634,343,000 | $181,165,000 | $119,882,000 | $16,653,000 |
| Total Equity Gross Minority Interest | $634,343,000 | $181,165,000 | $119,882,000 | $16,653,000 |
| Stockholders Equity | $634,343,000 | $181,165,000 | $119,882,000 | $16,653,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $57,000 | $22,000 | $0 |
| Retained Earnings | $-728,164,000 | $-515,770,000 | $-222,807,000 | $-116,001,000 |
| Other Equity Adjustments | - | $57,000 | $22,000 | - |
| Other | ||||
| Ordinary Shares Number | $113,133,199 | $64,460,829 | $43,251,778 | $12,128,843 |
| Share Issued | $113,133,199 | $64,460,829 | $43,251,778 | $12,128,843 |
| Tangible Book Value | $634,343,000 | $181,165,000 | $119,882,000 | $16,653,000 |
| Invested Capital | $634,343,000 | $181,165,000 | $119,882,000 | $16,653,000 |
| Working Capital | $615,787,000 | $167,032,000 | $122,874,000 | $15,318,000 |
| Capital Lease Obligations | $3,855,000 | $4,832,000 | $1,650,000 | $291,000 |
| Total Capitalization | $634,343,000 | $181,165,000 | $119,882,000 | $16,653,000 |
| Additional Paid In Capital | $1,362,496,000 | $696,872,000 | $342,663,000 | $132,653,000 |
| Capital Stock | $11,000 | $6,000 | $4,000 | $1,000 |
| Common Stock | $11,000 | $6,000 | $4,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $3,855,000 | $4,769,000 | $1,340,000 | $62,000 |
| Current Deferred Revenue | $0 | $6,941,000 | $10,493,000 | $0 |
| Current Capital Lease Obligation | $0 | $63,000 | $310,000 | $229,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,527,000 | $5,861,000 | $4,170,000 | $1,874,000 |
| Current Accrued Expenses | $26,498,000 | $19,275,000 | $2,813,000 | $2,742,000 |
| Net PPE | $17,614,000 | $14,391,000 | $3,637,000 | $965,000 |
| Accumulated Depreciation | $-6,370,000 | $-4,749,000 | $-3,908,000 | $-3,451,000 |
| Gross PPE | $23,984,000 | $19,140,000 | $7,545,000 | $4,416,000 |
| Leases | $4,164,000 | $1,636,000 | $233,000 | $194,000 |
| Construction In Progress | $5,548,000 | $3,297,000 | $0 | - |
| Other Properties | $10,580,000 | $9,501,000 | $5,386,000 | $3,681,000 |
| Machinery Furniture Equipment | $714,000 | $428,000 | $362,000 | $257,000 |
| Buildings And Improvements | $2,978,000 | $4,278,000 | $1,564,000 | $284,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $73,952,000 | $39,463,000 | $0 |
| Non Current Deferred Revenue | - | $0 | $5,489,000 | $0 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-206,850,000 | $-164,302,000 | $-8,399,000 | $-28,938,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-190,919,000 | $-110,794,000 | $-7,568,000 | $-28,690,000 |
| Cash Flow From Continuing Operating Activities | $-190,919,000 | $-110,794,000 | $-7,568,000 | $-28,690,000 |
| Operating Gains Losses | $896,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-15,931,000 | $-53,508,000 | $-831,000 | $-248,000 |
| Investing Cash Flow | $60,803,000 | $-85,063,000 | $-30,484,000 | $-248,000 |
| Cash Flow From Continuing Investing Activities | $60,803,000 | $-85,063,000 | $-30,484,000 | $-248,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $678,900,000 | $250,002,000 | $125,034,000 | $0 |
| Financing Cash Flow | $640,357,000 | $240,529,000 | $116,408,000 | $32,000 |
| Cash Flow From Continuing Financing Activities | $640,357,000 | $240,529,000 | $116,408,000 | $32,000 |
| Net Other Financing Charges | $-39,456,000 | $-15,228,000 | $-8,997,000 | - |
| Net Common Stock Issuance | $678,900,000 | $250,002,000 | $125,034,000 | $0 |
| Common Stock Issuance | $678,900,000 | $250,002,000 | $125,034,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $653,692,000 | $143,451,000 | $98,779,000 | $20,423,000 |
| Beginning Cash Position | $143,451,000 | $98,779,000 | $20,423,000 | $49,329,000 |
| Changes In Cash | $510,241,000 | $44,672,000 | $78,356,000 | $-28,906,000 |
| Proceeds From Stock Option Exercised | $913,000 | $5,755,000 | $371,000 | $32,000 |
| Net Investment Purchase And Sale | $76,734,000 | $-31,555,000 | $-38,929,000 | $0 |
| Sale Of Investment | $200,000,000 | $155,000,000 | $0 | - |
| Purchase Of Investment | $-123,266,000 | $-186,555,000 | $-38,929,000 | $0 |
| Net Intangibles Purchase And Sale | $-6,246,000 | $-46,335,000 | $0 | - |
| Purchase Of Intangibles | $-6,246,000 | $-46,335,000 | $0 | - |
| Net PPE Purchase And Sale | $-9,685,000 | $-7,173,000 | $-831,000 | $-248,000 |
| Purchase Of PPE | $-9,685,000 | $-7,173,000 | $-831,000 | $-248,000 |
| Change In Working Capital | $-15,227,000 | $14,874,000 | $11,997,000 | $2,243,000 |
| Change In Other Working Capital | $-6,941,000 | $-9,041,000 | $15,982,000 | - |
| Change In Other Current Liabilities | $-166,000 | $-67,000 | $153,000 | $-229,000 |
| Change In Payables And Accrued Expense | $-4,631,000 | $23,076,000 | $6,000 | $-2,599,000 |
| Change In Accrued Expense | $4,533,000 | $13,550,000 | $614,000 | $-1,922,000 |
| Change In Payable | $-9,164,000 | $9,526,000 | $-608,000 | $-677,000 |
| Change In Account Payable | $-9,164,000 | $9,526,000 | $-608,000 | $-677,000 |
| Change In Prepaid Assets | $-3,489,000 | $906,000 | $-4,144,000 | $5,071,000 |
| Other Non Cash Items | $10,000,000 | $152,344,000 | $80,802,000 | - |
| Stock Based Compensation | $25,690,000 | $15,748,000 | $6,223,000 | $5,332,000 |
| Amortization Of Securities | $-2,839,000 | $-2,899,000 | $-512,000 | $0 |
| Depreciation Amortization Depletion | $2,955,000 | $2,102,000 | $728,000 | $631,000 |
| Depreciation And Amortization | $2,955,000 | $2,102,000 | $728,000 | $631,000 |
| Depreciation | $2,955,000 | $2,102,000 | $728,000 | $631,000 |
| Gain Loss On Sale Of PPE | $896,000 | $0 | - | - |
| Net Income From Continuing Operations | $-212,394,000 | $-292,963,000 | $-106,806,000 | $-36,896,000 |
| Net Business Purchase And Sale | - | $0 | $9,276,000 | $0 |
| Sale Of Business | - | $0 | $9,276,000 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-25